Search Results for "Alopecia"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Alopecia. Results 81 to 90 of 97 total matches.

Elafibranor (Iqirvo) for Primary Biliary Cholangitis

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024  (Issue 1718)
pain, alopecia, 151.50 Urso Forte (Allergan) 500 mg scored tabs divided doses diarrhea, nausea ...
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated receptor (PPAR) agonist, has been granted accelerated approval by the FDA for treatment of primary biliary cholangitis (PBC) in adults. It is indicated for use in combination with ursodeoxycholic acid (ursodiol, UDCA; Urso, and others) in patients with an inadequate response to UDCA alone and as monotherapy in those unable to tolerate UDCA.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):202-4   doi:10.58347/tml.2024.1718b |  Show IntroductionHide Introduction

Seladelpar (Livdelzi) for Primary Biliary Cholangitis

   
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025  (Issue 1720)
pain, alopecia, diarrhea, 151.50 Urso Forte (Allergan) 500 mg scored tabs 2-4 divided doses nausea ...
Seladelpar (Livdelzi – Gilead), a peroxisome proliferator-activated receptor (PPAR)-delta agonist, has received accelerated approval from the FDA for use in combination with ursodeoxycholic acid (ursodiol, UDCA; Urso Forte, and generics) for treatment of primary biliary cholangitis (PBC) in adults who had an inadequate response to UDCA and as monotherapy in those unable to tolerate UDCA. Accelerated approval was based on a reduction in alkaline phosphatase (ALP) levels. Seladelpar is the second PPAR agonist to be approved in the US for this indication; elafibranor (Iqirvo)...
Med Lett Drugs Ther. 2025 Jan 20;67(1720):13-5   doi:10.58347/tml.2025.1720d |  Show IntroductionHide Introduction

Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
in the clinical trial were nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia ...
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki (Enhertu – Daiichi-Sankyo/AstraZeneca), an IV HER2-directed monoclonal antibody linked to the topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):182-4 |  Show IntroductionHide Introduction

Drugs for Female Sexual Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2010  (Issue 1353)
effects of chronic testosterone use in women include hirsutism, acne, clitoromegaly, alopecia, lower HDL ...
Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.
Med Lett Drugs Ther. 2010 Dec 13;52(1353):100-2 |  Show IntroductionHide Introduction

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
– Ruxience (Pfizer) 7168.00 Mitoxantrone – generic ~60%14 12 mg/m2 IV q3 months Nausea, alopecia, amenorrhea ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
effects of isotretinoin include cheilitis, epistaxis, dry skin, alopecia, eczema, skin fragility ...
Acne is common among adolescents and adults. Guidelines for treatment of acne were last published by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20   doi:10.58347/tml.2024.1695a |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
Myelosuppression, opportunistic infections, alopecia, rash, stomatitis, vomiting, diarrhea, GI hemorrhage ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9   doi:10.58347/tml.2023.1680d |  Show IntroductionHide Introduction

Chemotherapy for Esophageal, Gastric and Colorectal Cancers

   
Treatment Guidelines from The Medical Letter • Aug 01, 2006  (Issue 48)
, alopecia, mucositis, diarrhea, peripheral neuropathy, fatigue and asthenia. A fluid retention syndrome ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Treat Guidel Med Lett. 2006 Aug;4(48):55-60 |  Show IntroductionHide Introduction

Drugs for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020  (Issue 1600)
targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb ...
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
occurs frequently with leflunomide. Reversible alopecia, rash, hypertension, myelosuppression ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction